RxDoctor Payments Data

Bachar Elsaadi, MD

Family Medicine · Fort Worth, TXNPI 1326421918

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Sunovion Pharmaceuticals Inc.. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.

$62in general payments, 2019–2025

Across 6 payments — averaging $10.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$62
$1,085,130in research payments, 2019–2025

Across 40 payments — averaging $27,128 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$1.1M

What the payments were for

  • Food & beverage$62100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sunovion Pharmaceuticals Inc.6$62

How this compares

$62 in reported general payments places this provider in the 15th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$408,447
Medicare patients
504
Services billed
2,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban328$92,768
NuedextaDextromethorphan Hbr/Quinidine31$25,035
OzempicSemaglutide23$23,603
JardianceEmpagliflozin73$21,797
JanuviaSitagliptin Phosphate53$15,014
AptiomEslicarbazepine Acetate24$14,991
GemtesaVibegron58$14,686
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,141
Pantoprazole Sodium233$8,840
MyrbetriqMirabegron33$8,123
FarxigaDapagliflozin Propanediol25$7,834
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog48$6,787
Glucagon Emergency KitGlucagon23$6,766
XareltoRivaroxaban19$6,377
Memantine Hcl163$5,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$62$14,99124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →